However, there was no significant difference in AD-related pathological changes between NTSCs-H and NTSCs-SC treatment groups.<h4>Conclusions</h4>Our findings suggest that SSEA3/CD105 positivity is a potential marker of NTSC therapeutic efficacy for the treatment of AD. The gene discussed is ENG; the disease is Alzheimer disease.